Using 99mTc-P137 SPECTCT Imaging to Improve Diagnosis and Staging of Prostate Cancer

What this Trial Is About

Researchers are evaluating the use of a radioactive molecular probe called 99mTc-P137 combined with SPECTCT imaging to improve the diagnosis of prostate cancer. The study aims to enhance early detection, accurate tumor staging, treatment decisions, and prognosis assessment for patients suspected of having prostate cancer. This prospective study compares imaging results to surgical and pathological findings to establish clinical value. Participants will receive an injection of the 99mTc-P137 tracer followed by SPECTCT scans performed 2 hours after injection. Additional imaging findings will be collected up to 7 days after injection to optimize the imaging and diagnostic process. This study focuses on patients planning surgical resection or biopsy, using the probe to detect prostate cancer lesions accurately. During the study, participants will undergo multiple imaging assessments and provide clinical laboratory results including blood tests and PSA levels. Researchers will monitor the diagnostic accuracy of 99mTc-P137 SPECTCT imaging against pathological results. Participants must be able to complete the procedures independently, and their imaging and clinical data will be used to evaluate the probes value in prostate cancer diagnosis and prognosis.

99mTc-P137 SPECT/CT in Prostate Cancer